Pharmafile Logo

Xyphos

- PMLiVE

Baxalta makes $1.7bn play for slice of CAR-T market

Three-year alliance with Precision BioSciences to expand immuno-oncology portfolio

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Research Partnership

- PMLiVE

Astellas appoints new president of its Americas operations

James Robinson replaces Masao Yoshida

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Research Partnership

- PMLiVE

Baxalta inks $1.6bn immuno-oncology deal with Symphogen

Comes as the company's takeover negotiations with Shire continue

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

Astellas sells dermatology unit to Leo for €675m

Continuesthe company's restructuring drive

- PMLiVE

Astellas appoints Peter Sandor as head of oncology

He joins the company from Amgen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links